Jazz Pharmaceuticals (JAZZ) FY2014 results: revenue $1.2 billion, up 34.4% on the year
Jazz Pharmaceuticals plc (JAZZ) reported revenue of $1.2 billion for fiscal 2014, the year ended 31 December 2014, up 34.4% on the year before. Net income was $58 million, down 73.0%, and diluted earnings per share $0.93. The figures are the company's own, from the 10-K it filed with the SEC on 24 February 2015.
Revenue
$1.2 billion
+34.4% on the year
FY2009FY2014
Operating margin
16.7%
39.0% a year earlier
FY2009FY2014
Net income
$58 million
-73.0% on the year
FY2009FY2014
Diluted EPS
$0.93
-73.5% on the year
FY2009FY2014
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2014
FY2013
FY2012
On the year
Last 8 years
Revenue
1,173
872
586
+34.4%
Research and development
85.2
41.6
20.5
+104.6%
Selling, general and administrative
406
304
224
+33.5%
Operating income
196
340
198
-42.5%
Operating margin
16.7%
39.0%
33.8%
Pre-tax income
152
308
177
-50.8%
Income tax
94.2
91.6
-83.8
+2.8%
Effective tax rate
62.2%
29.8%
-47.2%
Net income
58.4
216
289
-73.0%
Net margin
5.0%
24.8%
49.2%
Diluted EPS
$0.93
$3.51
$4.79
-73.5%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2014
FY2013
FY2012
On the year
Last 8 years
Operating cash flow
408
288
250
+41.3%
Capital expenditure
36.3
10.0
6.0
+264.3%
Free cash flow
371
278
244
+33.3%
Free cash flow margin
31.7%
31.9%
41.6%
Cash from investing
-1,068
-16.3
-395
Cash from financing
711
-23.9
449
Depreciation and amortisation
134
82.1
74.2
+62.8%
Share-based compensation
69.6
44.6
23.0
+56.3%
Buybacks
42.2
136
0.0
-69.1%
Diluted shares, weighted
63m
62m
60m
+1.7%
Shares outstanding at period end
61m
58m
58m
+4.8%
Balance sheet
$ million
FY2014
FY2013
FY2012
On the year
Last 8 years
Shareholders' equity
1,371
1,296
1,121
+5.8%
Non-controlling interest
0.1
0.0
n/a
Debt
1,342
550
457
+144.1%
Other liabilities
625
393
388
+59.2%
Total liabilities and equity
3,339
2,238
1,966
+49.2%
Fixed assets
58.4
14.2
7.3
+309.7%
Goodwill
703
450
443
+56.0%
Intangible assets
1,437
812
870
+76.9%
Investments
n/a
n/a
0.0
Cash and equivalents
684
637
387
+7.5%
Receivables
186
125
75.5
+49.3%
Inventory
30.0
28.7
26.5
+4.8%
Other assets
240
171
157
+40.2%
Total assets
3,339
2,238
1,966
+49.2%
10-K for the year ended 31 December 2014, filed 24 February 2015: the filing.